The Daily Biotech Pulse: Limited Use Of JNJ’s COVID-19 Shot, Myovant-Pfizer’s Relugolix Application Delayed, Gain Therapeutics’ Parkinson’s Data
Here's a roundup of top developments in the biotech space over the last 24 hours.
Gain Therapeutics Highlights Presentation Of Pre-Clinical Data On Its Small Molecule Lead Compound In Parkinson’s At Recent World Congress on Parkinson’s Disease and Related Disorders
Gain Therapeutics, Inc. (NASDAQ:GANX) (“Gain”, or the “Company”), a biotechnology company applying its proprietary computational discovery platform to identify novel targets and small molecule
Gain Therapeutics Shares Skyrocket After Preclinical Data From Parkinson’s Program
Gain Therapeutics Inc (NASDAQ: GANX) has
Gain Therapeutics Presents Data On Its Small Molecule Lead Compound In GBA1 Parkinson’s Disease At The 2022 Synuclein Meeting
Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain"), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators identified with its proprietary
B. Riley Securities Maintains Buy on Gain Therapeutics, Lowers Price Target to $16
B. Riley Securities analyst Mayank Mamtani maintains Gain Therapeutics (NASDAQ:GANX) with a Buy and lowers the price target from $21 to $16.
HC Wainwright & Co. Initiates Coverage On Gain Therapeutics with Buy Rating, Announces Price Target of $12
HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Gain Therapeutics (NASDAQ:GANX) with a Buy rating and announces Price Target of $12.
Gain Therapeutics Presents Highlights Presentation Of Data On Structurally Targeted Allosteric Regulators In both Parkinson’s And Alzheimer’s Disease At AD/PD 2022 Conference
Study results provide additional validation that SEE-Tx platform identifies brain-penetrant small molecules ideally suited for CNS diseases caused by protein misfolding
Demonstration of in vitro and in vivo
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.